Literature DB >> 12850220

Regulated endocytosis of opioid receptors: cellular mechanisms and proposed roles in physiological adaptation to opiate drugs.

Mark von Zastrow1, Adena Svingos, Helena Haberstock-Debic, Chris Evans.   

Abstract

Opiate drugs such as morphine and heroin are among the most effective analgesics known. Prolonged or repeated administration of opiates produces adaptive changes in the nervous system that lead to reduced drug potency or efficacy (tolerance), as well as physiological withdrawal symptoms and behavioral manifestations such as craving when drug use is terminated (dependence). These adaptations limit the therapeutic utility of opiate drugs, particularly in the treatment of chronically painful conditions, and are thought to contribute to the highly addictive nature of opiates. For many years it has been proposed that physiological tolerance to opiate drugs is associated with a modification of the number or functional activity of opioid receptors in specific neurons. We now understand certain mechanisms of opioid receptor desensitization and endocytosis in considerable detail. However, the functional roles that these mechanisms play in the complex physiological adaptation of the intact nervous system to opiates are only beginning to be explored.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12850220     DOI: 10.1016/s0959-4388(03)00069-2

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  47 in total

1.  Cholesterol regulates micro-opioid receptor-induced beta-arrestin 2 translocation to membrane lipid rafts.

Authors:  Yu Qiu; Yan Wang; Ping-Yee Law; Hong-Zhuan Chen; Horace H Loh
Journal:  Mol Pharmacol       Date:  2011-04-25       Impact factor: 4.436

2.  Chronic morphine treatment reduces recovery from opioid desensitization.

Authors:  Vu C Dang; John T Williams
Journal:  J Neurosci       Date:  2004-09-01       Impact factor: 6.167

3.  Ubiquitination in the first cytoplasmic loop of μ-opioid receptors reveals a hierarchical mechanism of lysosomal down-regulation.

Authors:  James N Hislop; Anastasia G Henry; Mark von Zastrow
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

4.  Morphine induces μ opioid receptor endocytosis in guinea pig enteric neurons following prolonged receptor activation.

Authors:  Simona Patierno; Laura Anselmi; Ingrid Jaramillo; David Scott; Rachel Garcia; Catia Sternini
Journal:  Gastroenterology       Date:  2010-11-09       Impact factor: 22.682

5.  Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands.

Authors:  Brady K Atwood; James Wager-Miller; Christopher Haskins; Alex Straiker; Ken Mackie
Journal:  Mol Pharmacol       Date:  2011-11-07       Impact factor: 4.436

Review 6.  Look before leaping: combined opioids may not be the rave.

Authors:  Mellar P Davis; Susan B LeGrand; Ruth Lagman
Journal:  Support Care Cancer       Date:  2005-07-06       Impact factor: 3.603

Review 7.  Mu-opioid receptor desensitization: is morphine different?

Authors:  Mark Connor; Peregrine B Osborne; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

Review 8.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 9.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

10.  Herkinorin analogues with differential beta-arrestin-2 interactions.

Authors:  Kevin Tidgewell; Chad E Groer; Wayne W Harding; Anthony Lozama; Matthew Schmidt; Alfred Marquam; Jessica Hiemstra; John S Partilla; Christina M Dersch; Richard B Rothman; Laura M Bohn; Thomas E Prisinzano
Journal:  J Med Chem       Date:  2008-04-02       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.